Attitudes toward molecular testing for personalized cancer therapy

Cancer

Volumn 121, Issue 2, 2015, Pages 243-250

  Yusuf, Rafeek A ^a   Rogith, Deevakar ^a   Hovick, Shelly R A ^b   Peterson, Susan K ^c   Burton Chase, Allison M ^d   Fellman, Bryan M ^c   Li, Yisheng ^c   McKinney, Carolyn ^c   Bernstam, Elmer V ^a,e   Meric Bernstam, Funda ^c  

^a UNIVERSITY OF TEXAS   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^e UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Biomarkers; Disparities; Molecular testing; Personalized cancer therapy; Questionnaire; Survey

Indexed keywords

ADULT; ARTICLE; BREAST CANCER; CANCER THERAPY; CLINICAL RESEARCH; CONTROLLED STUDY; DRUG APPROVAL; EXPERIMENTAL THERAPY; FEMALE; HEALTH INSURANCE; HUMAN; MAJOR CLINICAL STUDY; MINIMALLY INVASIVE PROCEDURE; MOLECULAR TESTING; ONCOLOGICAL PROCEDURE; PATIENT ASSESSMENT; PATIENT ATTITUDE; PERSONALIZED MEDICINE; QUESTIONNAIRE; RACE DIFFERENCE; TUMOR BIOPSY; AGED; ANCESTRY GROUP; ATTITUDE TO HEALTH; BREAST NEOPLASMS; CAUCASIAN; EDUCATIONAL STATUS; EPIDEMIOLOGY; ETHNOLOGY; GENETIC SCREENING; HEALTH CARE DISPARITY; MARRIAGE; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; PROCEDURES; PSYCHOLOGY; STATISTICS AND NUMERICAL DATA; UNITED STATES;

ANTINEOPLASTIC AGENT;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ATTITUDE TO HEALTH; BREAST NEOPLASMS; CONTINENTAL POPULATION GROUPS; EDUCATIONAL STATUS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC TESTING; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEALTHCARE DISPARITIES; HUMANS; MARITAL STATUS; MIDDLE AGED; MOLECULAR TARGETED THERAPY; PATIENT ACCEPTANCE OF HEALTH CARE; PRECISION MEDICINE; SURVEYS AND QUESTIONNAIRES; TEXAS;

EID: 84920854800     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28966     Document Type: Article

References (39)

1. Mendelsohn J. Customized cancer medicine: are we ready for what it will take? Paper presented at: 47th Annual Meeting of the American Society of Clinical Oncology; 2011; Chicago, IL.
2. Council of Drugs. A Handbook of Useful Drugs. Chicago, IL: Press of the American Medical Association; 1913.
3. Trudeau ME, Bombard Y, Rozmovits L, Leighl NB, Deal K, Marshall D. The value of personalizing medicine: medical oncologists' and patients' perspective on genomic testing of breast tumor in chemotherapy treatment decisions. J Clin Oncol. 2012;30:e11000.
4. Treweek S, Doney A, Leiman D. Public attitudes to the storage of blood left over from routine general practice tests and its use in research. J Health Serv Res Policy. 2009;14:13-19.
5. Nelson DE, Kreps GL, Hesse BW, et al. The Health Information National Trend Survey (HINTS): development, design, and dissemination. J Health Commun. 2004;9:443-460.
6. Tupasela A, Sihvo S, Snell K, Jallinoja P, Aro AR, Hemminki E. Attitudes towards biomedical use of tissue sample collections, consent, and biobanks among Finns. Scand J Public Health. 2010;38:46-52.
7. Cousins G, McGee Hannah, Ring L, et al. Public perceptions of biomedical research: a survey of the general population in Ireland. Psychol Rep. 2005:Paper 8.
8. Kettis-Lindblad A, Ring L, Viberth E, Hansson MG. Genetic research and donation of tissue samples to biobanks. What do potential sample donors in the Swedish general public think? Eur J Public Health. 2006;16:433-440.
9. Ma Y, Dai H, Wang L, Zhu L, Zou H, Kong X. Consent for use of clinical leftover biosample: a survey among Chinese patients and the general public. PLoS One. 2012;7:e36050.
10. DeNavas-Walt C, Proctor BD, Smith JC. Income, poverty, and health insurance coverage in the United States: 2011. http://www.census.gov/prod/2012pubs/p60-243.pdf. Accessed June 2014.
11. Klitzman R, Appelbaum PS, Fyer A, et al. Researchers' views on return of incidental genomic research results: qualitative and quantitative findings. Genet Med. 2013;15:888-895.
12. Fabsitz RR, McGuire A, Sharp RR, et al. Ethical and practical guidelines for reporting genetic research results to study participants: updated guidelines from an NHLBI working group. Circ Cardiovasc Genet. 2010;3:574-580.
13. Meacham MC, Starks H, Burke W, Edwards K. Researcher perspectives on disclosure of incidental findings in genetic research. J Empir Res Human Res Ethics. 2010;5:31-41.
14. Elzinga K, Fernandez CV, Heng DYC, Tang PA. Returning research results to clinical trial participants: a survey of patients with cancer [abstract]. J Clin Oncol. 2011;29(suppl):2611.
15. Wendler D, Emanuel E. The debate over research on stored biological samples: what do sources think? Arch Intern Med. 2002;162:1457-1462.
16. Kaufman D, Murphy J, Scott J, Hudson K. Subjects matter: a survey of public opinions about a large genetic cohort study. Genet Med. 2008;10:831-839.
17. Patridge AH, Hackett N, Blood E, et al. Oncology physician and nurse practices and attitudes regarding offering clinical trial results to study participants. J Natl Cancer Inst. 2004;96:629-632.
18. Shalowitz DI, Miller FG. Communicating the results of clinical research to participants: attitudes, practices, and future directions. PLoS Med. 2008;5:e91.
19. Hosmer DW, Lemeshow S. Assessing the fit of the model. In: Applied Logistic Regression. Hoboken, NJ: John Wiley & Sons; 2005:143-202.
20. Kerath SM, Klein G, Kern M, et al. Beliefs and attitudes towards participating in genetic research - a population based cross-sectional study. BMC Public Health. 2013;13:114.
21. Byrne MM, Tannenbaum SL, Gluck S, Hurley J, Antoni M. Participation in cancer clinical trials: why are patients not participating? Med Decis Making. 2014;34:116-126.
22. Kwiatkowski K, Coe K, Bailar JC, Swanson GM. Inclusion of minorities and women in cancer clinical trials, a decade later: have we improved? Cancer. 2013;116:2956-2963.
23. Ford ME, Siminoff LA, Pickelsimer E, et al. Unequal burden of disease, unequal participation in clinical trials: solutions from African American and Latino community members. Health Soc Work. 2013;38:29-38.
24. Hirano SA, Murray SB, Harvey VM. Reporting, representation, and subgroup analysis of race and ethnicity in published clinical trials of atopic dermatitis in the United States between 2000 and 2009. Pediatr Dermatol. 2012;29:749-755.
25. Svensson K, Ramirez OF, Peres F, Barnett M, Claudio L. Socioeconomic determinants associated with willingness to participate in medical research among a diverse population. Contemp Clin Trials. 2012;33:1197-1205.
26. Corbie-Smith G, Isler MR, Miles MS, Banks B. Community-based HIV clinical trials: an integrated approach in underserved, rural, minority communities. Prog Community Health Partnersh. 2012;6:121-129.
27. Coakley M, Fadiran EO, Parrish LJ, Griffith RA, Weiss E, Carter C. Dialogues on diversifying clinical trials: successful strategies for engaging women and minorities in clinical trials. J Womens Health. 2012;21:713-716.
28. Coronado GD, Ondelacy S, Schwarz Y, Duggan C, Lampe JW, Neuhouser ML. Recruiting underrepresented groups into the Carbohydrate and Related Biomarkers (CARB) cancer prevention feeding study. Contemp Clin Trials. 2012;33:641-646.
29. Brown SD, Lee K, Schoffman DE, King AC, Crawley LM, Kiernan M. Minority recruitment into clinical trials: experimental findings and practical implications. Contemp Clin Trials. 2012;33:620-623.
30. Mendoza DB, Williams MT, Chapman LK, Powers M. Minority inclusion in randomized clinical trials of panic disorder. J Anxiety Disord. 2012;26:574-582.
31. Green BB, Bogart A, Chubak J, et al. Nonparticipation in a population-based trial to increase colorectal cancer screening. Am J Prev Med. 2012;42:390-397.
32. De las Nueces D, Hacker K, DiGirolamo A, Hicks LS. A systematic review of community-based participatory research to enhance clinical trials in racial and ethnic minority groups. Health Serv Res. 2012; 47(3 pt 2):1363-1386.
33. Kim ES, Herbst RS, Wistuba II, et al. The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov. 2011;1:44-53.
34. Vaz-Luis I, Zeghibe CA, Frank ES, et al. Prospective clinical experience with research biopsies in breast cancer patients. Breast Cancer Res Treat. 2013;142:203-209.
35. Hong DS, George GC, Iwuanyanwu EC, et al. Factors related to biopsy willingness in patients with advanced cancer in a phase I clinic for molecularly targeted therapy. J Cancer Res Clinic Oncol 2013;139:963-970.
36. Advani AS, Atkeson B, Brown CL, et al. Barriers to the participation of African-American patients with cancer in clinical trials: a pilot study. Cancer. 2003;97:1499-1506.
37. Wolf SM, Crock BN, Van Ness B, et al. Managing incidental findings and research results in genomic research involving biobanks and archived data sets. Genet Med. 2012;14:361-384.
38. Office of Biorepositories and Biospecimen Research. Workshop on release of research results to participants in biospecimen studies. http://biospecimens.cancer.gov/global/pdfs/NCI-Return-Research-Results-Summary-Final-508.pdf. Accessed November 25, 2012.
39. Green RC, Berg JS, Grody WW, et al. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet Med. 2013;15:565-574.